StockNews.AI
UTHR
Forbes
2 days

United Therapeutics: Is UTHR Stock Still A Buy At $400?

1. UTHR stock surged 33% after positive IPF trial results. 2. Tyvaso could add $4-5 billion in peak sales if approved. 3. Company exhibits strong fundamentals, viewing UTHR as attractive. 4. UTHR's financial metrics outperform S&P 500 benchmarks significantly. 5. Stock shows resilience during past market downturns.

9m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical trial results can lead to increased revenue potential for UTHR, as seen when other biopharma stocks soared post-FDA approvals.

How important is it?

The article highlights key growth opportunities from clinical results and solid financial position, driving investor interest.

Why Long Term?

Continued growth is expected from Tyvaso's expanded market, likely benefitting UTHR over the next 3–5 years.

Related Companies

Related News